Op18/stathmin对肿瘤细胞耐药性的调控  

Regulation of the drug-resistance of carcinoma cells mediated by Op18/stathmin

作　　者：林雪迟[1] 廖迎[1] 杨军[1] 苏丽君[1] 邹海蛟[1] 左亚婵[1] 邹林峰[1] 

机构地区：[1]长沙医学院医学检验系,长沙410219

出　　处：《生命的化学》2013年第3期265-268,共4页Chemistry of Life

基　　金：国家自然科学基金项目(81272274);湖南省自然科学基金项目(12JJ3104)

摘　　要：癌蛋白18(oncoprotein 18,Op18)/stathmin是一个直接调控微管动力学的高度保守的小分子磷蛋白,在肿瘤中高表达,与肿瘤的转移与侵袭等细胞生物学行为密切相关,是肿瘤治疗的一个靶标。Op18/stathmin受多种信号调控,参与介导肿瘤细胞的耐药的发生;靶向Op18/stathmin生物治疗成为耐药性肿瘤治疗的新尝试。Oncoprotein 18 （Op 18）/stathmin, a highly conserved small-molecule phosphoprotein regulating microtubule dynamics directly, is expressed at high levels in carcinoma cells. Opl8/stathmin has a close relationship with the migration and invasion of tumor cells, and is thought as a target of carcinoma treatment. Studies have demonstrated that Opl8/stathmin is regulated by a series of kinases to mediate the drug- resistance of carcinoma cells, so clinically the biological treatment targeting Opl 8/stathmin has become a useful new explore in drug-resitstant carcinomas.

关 键 词：Op18 肿瘤细胞 信号调控 耐药 靶向治疗 

分 类 号：R730.5[医药卫生—肿瘤]